Liraglutide (a long-acting GLP-1 analogue) and semaglutide (a GLP-1 receptor agonist) have been confirmed by clinical controlled trials to slow hepatic steatosis and non-alcoholic steatohepatitis, in addition to affecting insulin release (106, 107). Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.